Cooper completes strategic review and increases share repurchase authorization by $1 billion, while expecting Q4 2026 earnings per share of $1.05 to $1.09
Earnings Call Insights: Cooper Companies (COO) Q3 2026
Management Perspective
President and CEO Albert White stated: "This quarter saw several important developments, including earnings exceeding expectations, record free cash flow, robust growth in CooperSurgical's fertility business, and a favorable resolution of a significant tax matter."
President and CEO White noted: "However, at CooperVision, we proactively reduced channel inventory in the U.S., which weighed on performance and will continue to affect Q4."
President and CEO White said: "After a comprehensive evaluation of various alternatives, the board has completed its strategic review."
President and CEO White added: "Ultimately, the board unanimously determined that continuing to hold the company better serves shareholder interests compared to pursuing a transaction at this time."
President and CEO White stated: "We will focus more on profitable organic growth and disciplined capital allocation, including share repurchases."
President and CEO White reported: "CooperVision revenue was $717 million, broadly flat year-over-year."
President and CEO White remarked: "MiSight delivered another strong quarter with 20% organic growth."
President and CEO White stated: "Revenue was $349 million, with 3% organic growth."
President and CEO White said: "Within that, the fertility business had another steady quarter, growing 5% to $141 million."
Executive Vice President and CFO Brian Andrews said: "This quarter, following the successful completion of HMRC's review of our fiscal 2021 transfer of intellectual property and related assets to the U.K., we confirmed a significant one-time tax benefit of approximately $307 million."
Executive Vice President and CFO Andrews stated: "Non-GAAP EPS increased 4% to $1.15, including around $0.03 from tariff refunds."
Executive Vice President and CFO Andrews reported: "We generated $273 million in free cash flow, setting a new quarterly record for Cooper."
Executive Vice President and CFO Andrews noted: "The board approved increasing the share repurchase authorization by $1 billion, raising the remaining repurchase capacity to approximately $1.5 billion."
Outlook
Executive Vice President and CFO Andrews said: "For Q4, we expect consolidated revenue of $1.057 billion to $1.08 billion, corresponding to 0% to 2% organic growth."
Executive Vice President and CFO Andrews forecasted: "CooperVision revenue is expected between $692 million and $706 million, with organic growth declining 2% to flat."
Executive Vice President and CFO Andrews projected: "CooperSurgical revenue is expected between $364 million and $374 million, corresponding to 4% to 6% organic growth."
Executive Vice President and CFO Andrews stated: "Q4 non-GAAP effective tax rate is expected to be about 16%, resulting in non-GAAP EPS of $1.05 to $1.09."
Executive Vice President and CFO Andrews noted: "We expect Q4 overall to be similar to Q3, with the main differences being increased commercial investments at CooperVision, further foreign exchange headwinds, and reduced tariff refunds, which will pressure gross margin and operating margin."
Executive Vice President and CFO Andrews commented that it is "too early to provide guidance for fiscal 2027," but highlighted that about a 2% "GILTI scheduled increase" is expected to raise the non-GAAP tax rate "from around 15.5% this year to about 17.5% in fiscal 2027."
Financial Performance
Executive Vice President and CFO Andrews said: "Consolidated revenue for Q3 was $1.066 billion, growing about 1% on both reported and organic bases."
Executive Vice President and CFO Andrews noted: "Gross margin was 66.7%, down 60 basis points year-over-year."
Executive Vice President and CFO Andrews reported: "Operating margin improved by 30 basis points year-over-year to 26.3%."
Executive Vice President and CFO Andrews stated: "Interest expense was $21.5 million; non-GAAP effective tax rate was 15.3%."
Executive Vice President and CFO Andrews said: "This quarter, we repurchased $339 million of stock."
Executive Vice President and CFO Andrews noted: "We expect free cash flow of about $170 million, excluding approximately $272 million in litigation-related payments."
Q&A Session
Jonathan Block from Stifel asked: "Is this adjustment entirely related to inventory," rather than "fundamental factors?" President and CEO White responded: "Yes, Jon, it is all about inventory reduction."
Jeffrey Johnson from Baird asked: "What exactly drove the inventory reduction," and whether it will "continue into early 2027?" President and CEO White answered: "We have isolated it," and "we will address this in Q4, mostly substantially resolved."
Lei Huang from Wells Fargo inquired: "Can you quantify the impact of the U.S. inventory reduction," and what assumptions are built into Q4? President and CEO White replied: "If we had not taken the inventory reduction steps, the Americas would have reported about 5% growth in Q3," and "Q4 will see similar inventory reductions in the U.S."
Jason Bednar from Piper Sandler asked why the confidence in inventory reduction "is limited to the Americas issue," and why Europe, Middle East, and Africa (EMEA) do not show similar situations? President and CEO White answered: "EMEA is a market with much higher subscription penetration," and "we do not see this situation in EMEA."
Robert Marcus from JPMorgan asked about the current channel inventory level and how long it will take to complete. President and CEO White stated: "We... have completed half," "we finished half in Q3 and will complete the other half in Q4."
Joanne Wuensch from Citi asked whether growing within the "4% to 6% market growth range" next year is reasonable. President and CEO White answered: "Yes, that is reasonable," and "our challenge is execution ... turning contract wins into revenue and delivery."
Steven Lichtman from William Blair asked why the two businesses remain combined after the strategic review. President and CEO White responded: "This actually concerns the P&L," shared services allow the company to "generate strong profitability and robust cash flow."
Issie Kirby from Rothschild & Co Redburn asked about the China strategy and whether staying in the China market is worthwhile. President and CEO White responded: "On a consolidated basis, China represented less than 2% of revenue this quarter," and "we are considering whether to revive this business."
Sentiment Analysis
Jonathan Block of Stifel noted that expectations were previously higher, but now are "more muted;" analysts from Baird, Wells Fargo, Piper Sandler, and JPMorgan repeatedly pursued questions about inventory reduction. This reflects a slightly negative to negative analyst tone, focusing on performance visibility, drivers, and potential spillover effects.
President and CEO White's remarks, such as "Yes, Jon, it is all about inventory reduction" and "we have isolated it," along with "we... have completed half," indicate a somewhat positive tone regarding control; however, he also defensively emphasized execution gaps: "Our challenge is execution."
In Q2, management language focused on "record revenue" and "actively advancing discussions" in the strategic review; in Q3, the focus shifted to completing the review and specific channel actions, with analysts concentrating more on performance adjustments, inventory mechanisms, and 2027 planning.
Quarterly Comparison
In Q2, President and CEO White stated that the company was "actively advancing discussions" and planned to provide "clearer updates" on the strategic review; in Q3, he confirmed that "the board has completed the review" and chose to retain CooperSurgical.
Q2 commentary emphasized softness in Asia-Pacific and optimization of hydrogel business; Q3 emphasized channel inventory actions at CooperVision in the U.S., noting the guidance reduction was "solely related to channel inventory," as stated by President and CEO White.
Capital return stance shifted from expecting "significantly increased" repurchases in Q2 to actual execution and expanded authorization in Q3, including a $1 billion increase in authorization and $339 million repurchased in the quarter, according to Executive Vice President and CFO Andrews.
Risks and Concerns
President and CEO White stated: "We proactively reduced U.S. channel inventory," which "will continue to impact Q4;" management positioned mitigation as completion of related actions in Q4: "We will resolve this in Q4."
Executive Vice President and CFO Andrews noted that "Asia-Pacific continues to face near-term challenges;" in the myopia management business, China faces specific pressure: President and CEO White said, "It is the only market where MiSight actually declined."
Executive Vice President and CFO Andrews stated that margin pressures in Q4 include "increased commercial investments," "additional foreign exchange headwinds," and "reduced tariff refunds."
Final Key Points
Management highlighted Q3's focus on completing the strategic review and retaining CooperSurgical, while accelerating capital return and commercial investments. The primary investor concern during the call was CooperVision’s reduction of U.S. channel inventory, which management repeatedly described as a one-time event largely confined to Q3 and Q4; meanwhile, the company will increase spending to address what the CEO called an execution gap in turning contract wins into revenue. The CFO’s guidance shows that Q4 will be similar to Q3, with EPS from $1.05 to $1.09, with FX impact, reduced tariff refunds, and higher commercial investments adding pressure; meanwhile, the company also highlighted a substantial tax benefit related to HMRC and the expanded repurchase authorization.
Management Perspective
President and CEO Albert White stated: "This quarter saw several important developments, including earnings exceeding expectations, record free cash flow, robust growth in CooperSurgical's fertility business, and a favorable resolution of a significant tax matter."
President and CEO White noted: "However, at CooperVision, we proactively reduced channel inventory in the U.S., which weighed on performance and will continue to affect Q4."
President and CEO White said: "After a comprehensive evaluation of various alternatives, the board has completed its strategic review."
President and CEO White added: "Ultimately, the board unanimously determined that continuing to hold the company better serves shareholder interests compared to pursuing a transaction at this time."
President and CEO White stated: "We will focus more on profitable organic growth and disciplined capital allocation, including share repurchases."
President and CEO White reported: "CooperVision revenue was $717 million, broadly flat year-over-year."
President and CEO White remarked: "MiSight delivered another strong quarter with 20% organic growth."
President and CEO White stated: "Revenue was $349 million, with 3% organic growth."
President and CEO White said: "Within that, the fertility business had another steady quarter, growing 5% to $141 million."
Executive Vice President and CFO Brian Andrews said: "This quarter, following the successful completion of HMRC's review of our fiscal 2021 transfer of intellectual property and related assets to the U.K., we confirmed a significant one-time tax benefit of approximately $307 million."
Executive Vice President and CFO Andrews stated: "Non-GAAP EPS increased 4% to $1.15, including around $0.03 from tariff refunds."
Executive Vice President and CFO Andrews reported: "We generated $273 million in free cash flow, setting a new quarterly record for Cooper."
Executive Vice President and CFO Andrews noted: "The board approved increasing the share repurchase authorization by $1 billion, raising the remaining repurchase capacity to approximately $1.5 billion."
Outlook
Executive Vice President and CFO Andrews said: "For Q4, we expect consolidated revenue of $1.057 billion to $1.08 billion, corresponding to 0% to 2% organic growth."
Executive Vice President and CFO Andrews forecasted: "CooperVision revenue is expected between $692 million and $706 million, with organic growth declining 2% to flat."
Executive Vice President and CFO Andrews projected: "CooperSurgical revenue is expected between $364 million and $374 million, corresponding to 4% to 6% organic growth."
Executive Vice President and CFO Andrews stated: "Q4 non-GAAP effective tax rate is expected to be about 16%, resulting in non-GAAP EPS of $1.05 to $1.09."
Executive Vice President and CFO Andrews noted: "We expect Q4 overall to be similar to Q3, with the main differences being increased commercial investments at CooperVision, further foreign exchange headwinds, and reduced tariff refunds, which will pressure gross margin and operating margin."
Executive Vice President and CFO Andrews commented that it is "too early to provide guidance for fiscal 2027," but highlighted that about a 2% "GILTI scheduled increase" is expected to raise the non-GAAP tax rate "from around 15.5% this year to about 17.5% in fiscal 2027."
Financial Performance
Executive Vice President and CFO Andrews said: "Consolidated revenue for Q3 was $1.066 billion, growing about 1% on both reported and organic bases."
Executive Vice President and CFO Andrews noted: "Gross margin was 66.7%, down 60 basis points year-over-year."
Executive Vice President and CFO Andrews reported: "Operating margin improved by 30 basis points year-over-year to 26.3%."
Executive Vice President and CFO Andrews stated: "Interest expense was $21.5 million; non-GAAP effective tax rate was 15.3%."
Executive Vice President and CFO Andrews said: "This quarter, we repurchased $339 million of stock."
Executive Vice President and CFO Andrews noted: "We expect free cash flow of about $170 million, excluding approximately $272 million in litigation-related payments."
Q&A Session
Jonathan Block from Stifel asked: "Is this adjustment entirely related to inventory," rather than "fundamental factors?" President and CEO White responded: "Yes, Jon, it is all about inventory reduction."
Jeffrey Johnson from Baird asked: "What exactly drove the inventory reduction," and whether it will "continue into early 2027?" President and CEO White answered: "We have isolated it," and "we will address this in Q4, mostly substantially resolved."
Lei Huang from Wells Fargo inquired: "Can you quantify the impact of the U.S. inventory reduction," and what assumptions are built into Q4? President and CEO White replied: "If we had not taken the inventory reduction steps, the Americas would have reported about 5% growth in Q3," and "Q4 will see similar inventory reductions in the U.S."
Jason Bednar from Piper Sandler asked why the confidence in inventory reduction "is limited to the Americas issue," and why Europe, Middle East, and Africa (EMEA) do not show similar situations? President and CEO White answered: "EMEA is a market with much higher subscription penetration," and "we do not see this situation in EMEA."
Robert Marcus from JPMorgan asked about the current channel inventory level and how long it will take to complete. President and CEO White stated: "We... have completed half," "we finished half in Q3 and will complete the other half in Q4."
Joanne Wuensch from Citi asked whether growing within the "4% to 6% market growth range" next year is reasonable. President and CEO White answered: "Yes, that is reasonable," and "our challenge is execution ... turning contract wins into revenue and delivery."
Steven Lichtman from William Blair asked why the two businesses remain combined after the strategic review. President and CEO White responded: "This actually concerns the P&L," shared services allow the company to "generate strong profitability and robust cash flow."
Issie Kirby from Rothschild & Co Redburn asked about the China strategy and whether staying in the China market is worthwhile. President and CEO White responded: "On a consolidated basis, China represented less than 2% of revenue this quarter," and "we are considering whether to revive this business."
Sentiment Analysis
Jonathan Block of Stifel noted that expectations were previously higher, but now are "more muted;" analysts from Baird, Wells Fargo, Piper Sandler, and JPMorgan repeatedly pursued questions about inventory reduction. This reflects a slightly negative to negative analyst tone, focusing on performance visibility, drivers, and potential spillover effects.
President and CEO White's remarks, such as "Yes, Jon, it is all about inventory reduction" and "we have isolated it," along with "we... have completed half," indicate a somewhat positive tone regarding control; however, he also defensively emphasized execution gaps: "Our challenge is execution."
In Q2, management language focused on "record revenue" and "actively advancing discussions" in the strategic review; in Q3, the focus shifted to completing the review and specific channel actions, with analysts concentrating more on performance adjustments, inventory mechanisms, and 2027 planning.
Quarterly Comparison
In Q2, President and CEO White stated that the company was "actively advancing discussions" and planned to provide "clearer updates" on the strategic review; in Q3, he confirmed that "the board has completed the review" and chose to retain CooperSurgical.
Q2 commentary emphasized softness in Asia-Pacific and optimization of hydrogel business; Q3 emphasized channel inventory actions at CooperVision in the U.S., noting the guidance reduction was "solely related to channel inventory," as stated by President and CEO White.
Capital return stance shifted from expecting "significantly increased" repurchases in Q2 to actual execution and expanded authorization in Q3, including a $1 billion increase in authorization and $339 million repurchased in the quarter, according to Executive Vice President and CFO Andrews.
Risks and Concerns
President and CEO White stated: "We proactively reduced U.S. channel inventory," which "will continue to impact Q4;" management positioned mitigation as completion of related actions in Q4: "We will resolve this in Q4."
Executive Vice President and CFO Andrews noted that "Asia-Pacific continues to face near-term challenges;" in the myopia management business, China faces specific pressure: President and CEO White said, "It is the only market where MiSight actually declined."
Executive Vice President and CFO Andrews stated that margin pressures in Q4 include "increased commercial investments," "additional foreign exchange headwinds," and "reduced tariff refunds."
Final Key Points
Management highlighted Q3's focus on completing the strategic review and retaining CooperSurgical, while accelerating capital return and commercial investments. The primary investor concern during the call was CooperVision’s reduction of U.S. channel inventory, which management repeatedly described as a one-time event largely confined to Q3 and Q4; meanwhile, the company will increase spending to address what the CEO called an execution gap in turning contract wins into revenue. The CFO’s guidance shows that Q4 will be similar to Q3, with EPS from $1.05 to $1.09, with FX impact, reduced tariff refunds, and higher commercial investments adding pressure; meanwhile, the company also highlighted a substantial tax benefit related to HMRC and the expanded repurchase authorization.